PDCD1 and cancer: As ICIs, programmed cell death protein-1 (PD-1) inhibitors elicit a strong immune response by blocking the interaction of PD-1 with its ligands, programmed death ligand-1 [PD-L1] and PD-L2, which are highly expressed on cancer cells [14].